Asparaginase News and Research RSS Feed - Asparaginase News and Research

Asparaginase is a drug which is given at the same time as chemotherapy drugs. It is an enzyme which deprives leukaemia cells of essential nutrients so that they die.
Jazz Pharmaceuticals offers $500 million aggregate principal amount of exchangeable senior notes

Jazz Pharmaceuticals offers $500 million aggregate principal amount of exchangeable senior notes

Jazz Pharmaceuticals plc today announced that Jazz Investments I Limited, its wholly-owned subsidiary, priced its previously announced offering of $500 million aggregate principal amount of exchangeable senior notes due 2021. [More]
Sigma-Tau Rare Disease seeks EMA approval for use of Oncaspar for ALL treatment

Sigma-Tau Rare Disease seeks EMA approval for use of Oncaspar for ALL treatment

Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen. [More]
Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

Jazz Pharmaceuticals plc today presented data from the Phase 2b study evaluating JZP-110 (formerly known as ADX-N05) as a potential new treatment for the symptoms of excessive daytime sleepiness (EDS) in adults with narcolepsy. [More]
ERYTECH Pharma gets authorization to initiate Phase II study in pancreatic cancer

ERYTECH Pharma gets authorization to initiate Phase II study in pancreatic cancer

ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that the ANSM, French healthcare agency, has granted the authorization to start a Phase II study in second line treatment of patients affected by pancreatic cancer. [More]
FDA grants orphan drug designation to ERYTECH’s lead product for AML treatment

FDA grants orphan drug designation to ERYTECH’s lead product for AML treatment

ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer. [More]
Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder. [More]
Scientists discover novel mechanism that influences GAS virulence at early steps of necrotizing fasciitis

Scientists discover novel mechanism that influences GAS virulence at early steps of necrotizing fasciitis

How does Streptococcus pyogenes, or Group A streptococcus (GAS) — a bacterial pathogen that can colonize humans without causing symptoms or can lead to mild infections — also cause life-threatening diseases such as necrotizing fasciitis (commonly known as flesh-eating disease) and streptococcal toxic shock syndrome? [More]
Research may lead to potential treatment for deadly bacterial infections

Research may lead to potential treatment for deadly bacterial infections

Collaboration between the National University of Singapore (NUS) and The Hebrew University of Jerusalem (HUJ) on inflammation research may lead to a potential treatment for deadly bacterial infections [More]
Research opens way to possible new treatments for bacterial infections

Research opens way to possible new treatments for bacterial infections

​How does Streptococcus pyogenes, or Group A streptococcus (GAS) - a bacterial pathogen that can colonize humans without causing symptoms or can lead to mild infections - also cause life-threatening diseases such as necrotizing fasciitis (commonly known as flesh-eating disease) and streptococcal toxic shock syndrome? [More]
ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer. [More]
Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful intramuscular injection for more than 40 years, research suggests. [More]
Jazz Pharmaceuticals announces third quarter financial results and updated 2013 guidance

Jazz Pharmaceuticals announces third quarter financial results and updated 2013 guidance

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter ended September 30, 2013 and updated 2013 financial guidance. [More]
ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

ERYTECH, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces a fast take-off of its Phase IIb study in Acute Myeloid Leukemia. [More]
FDA clears ERYTECH Pharma' IND to start Phase I clinical trial of ERYASP in patients with ALL

FDA clears ERYTECH Pharma' IND to start Phase I clinical trial of ERYASP in patients with ALL

ERYTECH Pharma SA announced today that it has received clearance of its Investigational New Drug Application from the United States Food and Drug Administration to initiate a Phase I clinical trial of its product ERYASP, L-asparaginase loaded erythrocytes, in patients 40 years or older with newly diagnosed Acute Lymphoblastic Leukemia. [More]
AIBioTech announces implementation of L-asparaginase activity assay for pediatric ALL

AIBioTech announces implementation of L-asparaginase activity assay for pediatric ALL

AIBioTech is pleased to announce implementation of a new laboratory derived test to measure L-asparaginase levels in patients being treated with any of the current asparaginase drugs including: Oncaspar, Kidrolase, Erwinaze, and Elspar. [More]
Positive results from ERYTECH Pharma asparaginase Phase II trials on ALL

Positive results from ERYTECH Pharma asparaginase Phase II trials on ALL

The oral presentation will be held on June 17th 2012 by Prof. Dr. Hervé Dombret, Hospital Saint Louis, Paris (France) at the 17th Annual Meeting of European Hematology Association (EHA) in Amsterdam. [More]
EUSA Pharma acquires ASPAREC development and commercialization rights

EUSA Pharma acquires ASPAREC development and commercialization rights

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has acquired the exclusive worldwide development and commercialization rights to ASPAREC for the treatment of acute lymphoblastic leukemia (ALL) from Alizé Pharma. [More]
FDA approves EUSA's orphan drug ERWINAZE for acute lymphoblastic leukemia

FDA approves EUSA's orphan drug ERWINAZE for acute lymphoblastic leukemia

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that the US Food and Drug Administration (FDA) has approved its orphan drug ERWINAZE (asparaginase Erwinia chrysanthemi) for the treatment of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to E. coli-derived asparaginase. [More]
EUSA Pharma receives FDA approval for Erwinaze to treat ALL

EUSA Pharma receives FDA approval for Erwinaze to treat ALL

The U.S. Food and Drug Administration today approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegaspargase chemotherapy drugs used to treat ALL. [More]
E. coli asparaginase linked to relapses in ALL patients with special form of ATF5 gene

E. coli asparaginase linked to relapses in ALL patients with special form of ATF5 gene

One of the causes of resistance to cancer treatment in children is now beginning to be elucidated. Acute lymphoblastic leukemia patients with a particular form of the ATF5 gene are at higher risk of having a relapse when treated with E. coli asparaginase, a key chemotherapy drug for this type of leukemia. [More]